Loading...
•
Sep 30, 2024
Onconova Q3 2024 Earnings Report
Traws Pharma reported Q3 2024 financial results and provided a business update.
Key Takeaways
Traws Pharma reported a net loss of $8.5 million for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and short-term investments were approximately $5.4 million as of September 30, 2024. The company is advancing its antiviral programs and expects to commence Phase 2 studies in 2025.
Traws Pharma is making excellent progress with its clinical pipeline.
Phase 1 data for each of the antiviral programs for COVID and influenza are particularly exciting.
Tivoxavir marboxil pharmacokinetic data suggest it could be a single-dose treatment for influenza, including potential pandemic settings such as avian flu.
The net loss for the three months ended September 30, 2024 was $8.5 million, or $8.81 per basic and diluted common share.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...